Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer

Journal of Urology

Volumn 187, Issue 2, 2012, Pages 438-445

  Reis, Leonardo O ^a   Ferreira, Ubirajara ^a   Billis, Athanase ^a   Cagnon, Valéria H A ^a   Fávaro, Wagner J ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

BCG vaccine; enterotoxin B; methylnitrosourea; staphylococcal; urinary bladder; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; ENDOSTATIN; GELATINASE B; KI 67 ANTIGEN; SOMATOMEDIN C RECEPTOR; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOLOGY; IMMUNOREACTIVITY; NONHUMAN; NONMUSCLE INVASIVE BLADDER CANCER; PAPILLARY CARCINOMA; PAPILLARY HYPERPLASIA; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANIMALS; BCG VACCINE; ENTEROTOXINS; FEMALE; NEOPLASM INVASIVENESS; RATS; RATS, INBRED F344; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; URINARY BLADDER NEOPLASMS;

EID: 84855596559     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.10.022     Document Type: Article

References (30)

1. S.F. Altekruse, C.L. Kosary, M. Krapcho et al. SEER Cancer Statistics Review 1975-2007 Bethesda: National Cancer Institute http://seer.cancer.gov/csr/ 1975-2007/ based on November 2009 SEER data submission, posted to the SEER website 2010
2. Y. Zhang, C. Zhu, M.P. Curado et al. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease BJU Int May 18, 2011 Epub ahead of print
3. R. Montironi, A. Lopez-Beltran The 2004 WHO classification of bladder tumors: a summary and commentary Int J Surg Pathol 13 2005 143
4. M.D. Shelley, H. Kynaston, J. Court et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer BJU Int 88 2001 209
5. A.R. Zlotta, J.P. Van Vooren, O. Denis et al. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 87 2000 844
6. A.T. Ludwig, J.M. Moore, Y. Luo et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin- induced antitumor activity Cancer Res 64 2004 3386
7. M.P. Simons, M.A. O'Donnell, T.S. Griffith Role of neutrophils in BCG immunotherapy for bladder cancer Urol Oncol 26 2008 341
8. K. Petersson, G. Forsberg, B. Walse Interplay between superantigens and immunoreceptors Scand J Immunol 59 2004 345
9. F.G. Perabo, P.L. Willert, A. Wirger et al. Preclinical evaluation of superantigen (Staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer Int J Cancer 115 2005 591
10. L.O. Reis, W.J. Fávaro, U. Ferreira et al. Evolution on experimental animal model for upper urothelium carcinogenesis World J Urol 28 2010 499
11. D. Tomas, B. Krulin The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma Prostate 61 2004 324
12. P.U. Malmström, R.J. Sylvester, D.E. Crawford et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247
13. F.G. Perabo, P.L. Willert, A. Wirger et al. Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma Anticancer Res 25 2005 3565
14. A. Ojea, J.L. Nogueira, E. Solsona et al. A multicentre, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398
15. C.A. Power, G. Wei, P.A. Bretscher Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route Infect Immunol 66 1998 5743
16. R.S. DiPaola, E.C. Lattime Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy J Urol 178 2007 1840
17. C.P. Pavlovich, B.M. Krling, R.J. Stewart et al. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation J Urol 163 2000 2014
18. D.P. Poppas, C.P. Pavlovich, J. Folkman et al. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10 Urology 52 1998 268
19. S. Bernardini, S. Fauconnet, E. Chabannes et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer J Urol 166 2001 1275
20. K. Inoue, M. Kamada, J.W. Slaton The prognostic value of angiogenesis and metastasis related genes for progression of transitional cell carcinoma of renal pelvis and ureter Clin Cancer Res 8 2002 1863
21. K.P. Guan, H.Y. Ye, Z. Yan et al. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder Urology 61 2003 719
22. G. Bergers, R. Brekken, G. McMahon et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nature Cell Biol 2 2000 737
23. G. Hashimoto, I. Inoki, Y. Fujii et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165 J Biol Chem 277 2002 36288
24. J.L. Fowlkes, D.M. Serra, H. Nagase et al. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth Ann N Y Acad Sci 878 1999 696
25. M. Iwamura, M. Ishibe, P.M. Sluss et al. Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines Urol Res 21 1993 27
26. D. Metalli, F. Lovat, F. Tripodi et al. The insulin-like growth factor receptor 1 promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin Am J Pathol 176 2010 2997
27. T. Asakura, Y. Takano, M. Iki et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer J Urol 158 1997 385
28. C.C. Yang, K.C. Chu, W.M. Yeh The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression Urol Oncol 22 2004 1
29. J.P. Crew, T. O'Brien, M. Bradburn et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer Cancer Res 57 1997 5281
30. M.A. Rochester, N. Patel, B.W. Turney et al. The type 1 insulin like growth factor receptor is over-expressed in bladder cancer BJU Int 100 2007 1396